Article Text

AB0491 Treatment of Incident Sle, Results from the Finnish Nationwide Register 2000-2007
  1. P. Elfving1,
  2. K. Puolakka2,
  3. H. Kautiainen3,4,5,
  4. L. Virta6,
  5. T. Pohjolainen7,
  6. O. Kaipiainen-Seppänen1
  1. 1Department of Medicine, Kuopio University Hospital, Kuopio
  2. 2Department of Medicine, South Karelia Central Hospital, Lappeenranta
  3. 3Unit of Primary Health Care, Helsinki University Central Hospital
  4. 4Department of General Practice, University of Helsinki, Helsinki
  5. 5Unit of Primary Health Care, Kuopio University Hospital, Kuopio
  6. 6Research Department, Social Insurance Institution, Turku
  7. 7Rehabilitation Unit, Orton Hospital, Helsinki, Finland


Objectives To examine the first-year treatment of incident SLE.

Methods The Finnish nationwide register data on special reimbursement decisions for SLE medication costs was screened to identify the inception cohort of adult SLE patient years 2000-2007. The cohort was shared in 2-year time periods according to index date. The patients were linked to prescription register, which includes drugs purchased from pharmacies. Both registries are maintained by the Social Insurance Institution. The first-year treatment of incident SLE was evaluated.

Results A total of 566 subjects (87% females) were included in the incident cohort. Five percent of patients had not used any medicine and 80% had used some disease modifying anti-rheumatic drug (DMARD) during the first- year treatment. Prescriptions of mycophenolate mofetil as an initial treatment increased significantly throughout the time periods (2000-01, 2002-03, 2004-05 and 2006-07). Since year 2004 orally taken cyclophosphamide was not used in the first-year treatment of SLE.

Conclusions Mycophenolate mofetil had a significant increasing trend in treatment of incident SLE during the study time. During the follow-up use of hydroxychloroquine and disease modifying anti-rheumatic drugs (DMARDs) was stable.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.3086

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.